 |
|
|
| |
Hepatitis Delta Treatment Utilization in the United States:
An Analysis of Commercially Insured Adults With Hepatitis Delta Virus Infection
|
| |
| |
EASL 2023 June 23 Vienna
Robert J Wong1,2, Robert G Gish3, Joseph K Lim4, Ankita Kaushik5, Chong Kim5, Gary Leung6, Ira M Jacobson7
1Stanford University School of Medicine, Stanford, CA, USA; 2VA Palo Alto Healthcare System, Palo Alto, CA, USA; 3Hepatitis B Foundation, Doylestown, PA, USA; 4Yale School of Medicine, New Haven, CT, USA; 5HEOR - Global Value & Access, Gilead Sciences, Inc., Foster City, CA, USA; 6RWE - Epidemiology, Gilead Sciences, Inc., Foster City, CA, USA; 7NYU Grossman School of Medicine, New York, NY, USA
|
| |
|
|
|
|
|
